Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
Summary Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2020-09, Vol.190 (5), p.764-771 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 771 |
|---|---|
| container_issue | 5 |
| container_start_page | 764 |
| container_title | British journal of haematology |
| container_volume | 190 |
| creator | Fuster, José L. Molinos‐Quintana, Agueda Fuentes, Carolina Fernández, José M. Velasco, Pablo Pascual, Toñi Rives, Susana Dapena, José L. Sisinni, Luisa López‐Godino, Oriana Palomo, Pilar Villa‐Alcázar, Marta Bautista, Francisco González‐Vicent, Marta López‐Duarte, Mónica García‐Morín, Marina Ramos-Elbal, Eduardo Ramírez, Manuel |
| description | Summary
Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47·6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non‐haematological toxicity. The 12‐month overall survival and event‐free survival rates were 50·8 ± 26·4% and 38·9 ± 25·3% with blinatumomab, 45·8 ± 26% and 27·5 ± 25% with inotuzumab. |
| doi_str_mv | 10.1111/bjh.16647 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2441240828</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2441240828</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3887-59f7263cfe6bf2feeb88da277d39b21d49cb8044724abf5370a5a311d2506bd3</originalsourceid><addsrcrecordid>eNp1kctu1DAUhiMEokNhwQsgS2zoIq1vuQw7piod0EhTaSqxjHw56XiaxMEXUHhP3gfPpLDDG-scf_9_jvxn2VuCL0k6V_KwvyRlyatn2YKwssgp4eR5tsAYVznBvD7LXnl_wJgwXJCX2RmjjHDG60X2e9WZQYTY215IJAaNzGBD_BWPZWsdWiEFXYdGByo6nxpCxQCom_pxb2UnfDAKdRAfBfRGJDVSe9NpB8NHJJCD4KwfQQXzA5APUU-odbZHYQ9ok1Qn0TfrHs3wgG6djSOy7el1N4rB-D3aWWUgTMf2HWgjgksD19CLYDv7MJ123g5qLj7sbtbbu4vX2YtWdB7ePN3n2f3nm_vrdb7Z3n65_rTJFavrKi-WbUVLplooZUtbAFnXWtCq0mwpKdF8qWSNOa8oF7ItWIVFIRghmha4lJqdZ-9n29HZ7xF8aA42uiFNbCjnhHJc0zpRFzOl0ld4B20zOtMLNzUEN8f8mpRfc8ovse-eHKPsQf8j_waWgKsZ-Gk6mP7v1Ky-rmfLPwhhqIw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2441240828</pqid></control><display><type>article</type><title>Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><creator>Fuster, José L. ; Molinos‐Quintana, Agueda ; Fuentes, Carolina ; Fernández, José M. ; Velasco, Pablo ; Pascual, Toñi ; Rives, Susana ; Dapena, José L. ; Sisinni, Luisa ; López‐Godino, Oriana ; Palomo, Pilar ; Villa‐Alcázar, Marta ; Bautista, Francisco ; González‐Vicent, Marta ; López‐Duarte, Mónica ; García‐Morín, Marina ; Ramos-Elbal, Eduardo ; Ramírez, Manuel</creator><creatorcontrib>Fuster, José L. ; Molinos‐Quintana, Agueda ; Fuentes, Carolina ; Fernández, José M. ; Velasco, Pablo ; Pascual, Toñi ; Rives, Susana ; Dapena, José L. ; Sisinni, Luisa ; López‐Godino, Oriana ; Palomo, Pilar ; Villa‐Alcázar, Marta ; Bautista, Francisco ; González‐Vicent, Marta ; López‐Duarte, Mónica ; García‐Morín, Marina ; Ramos-Elbal, Eduardo ; Ramírez, Manuel ; Leukemia Working Group of the Spanish Society of Pediatric Hematology, Oncology (SEHOP) ; the Leukemia Working Group of the Spanish Society of Pediatric Hematology, Oncology (SEHOP)</creatorcontrib><description>Summary
Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47·6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non‐haematological toxicity. The 12‐month overall survival and event‐free survival rates were 50·8 ± 26·4% and 38·9 ± 25·3% with blinatumomab, 45·8 ± 26% and 27·5 ± 25% with inotuzumab.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.16647</identifier><identifier>PMID: 32314348</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>acute lymphoblastic leukaemia ; Acute lymphoblastic leukemia ; Adolescent ; Antibodies, Bispecific - administration & dosage ; Antibodies, Bispecific - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; blinatumomab ; Chemotherapy ; Child ; Child, Preschool ; Children ; Disease-Free Survival ; Female ; Hematology ; Humans ; Immunotherapy ; Infant ; inotuzumab ; Inotuzumab Ozogamicin - administration & dosage ; Inotuzumab Ozogamicin - adverse effects ; Leukemia ; Male ; Medical Oncology ; Minimal residual disease ; Monoclonal antibodies ; Oncology ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality ; relapse ; Remission ; Retrospective Studies ; Societies, Medical ; Spain - epidemiology ; Stem cell transplantation ; Survival Rate ; Toxicity</subject><ispartof>British journal of haematology, 2020-09, Vol.190 (5), p.764-771</ispartof><rights>2020 British Society for Haematology and John Wiley & Sons Ltd</rights><rights>2020 British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>Copyright © 2020 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3887-59f7263cfe6bf2feeb88da277d39b21d49cb8044724abf5370a5a311d2506bd3</citedby><cites>FETCH-LOGICAL-c3887-59f7263cfe6bf2feeb88da277d39b21d49cb8044724abf5370a5a311d2506bd3</cites><orcidid>0000-0002-4881-9440</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.16647$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.16647$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32314348$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fuster, José L.</creatorcontrib><creatorcontrib>Molinos‐Quintana, Agueda</creatorcontrib><creatorcontrib>Fuentes, Carolina</creatorcontrib><creatorcontrib>Fernández, José M.</creatorcontrib><creatorcontrib>Velasco, Pablo</creatorcontrib><creatorcontrib>Pascual, Toñi</creatorcontrib><creatorcontrib>Rives, Susana</creatorcontrib><creatorcontrib>Dapena, José L.</creatorcontrib><creatorcontrib>Sisinni, Luisa</creatorcontrib><creatorcontrib>López‐Godino, Oriana</creatorcontrib><creatorcontrib>Palomo, Pilar</creatorcontrib><creatorcontrib>Villa‐Alcázar, Marta</creatorcontrib><creatorcontrib>Bautista, Francisco</creatorcontrib><creatorcontrib>González‐Vicent, Marta</creatorcontrib><creatorcontrib>López‐Duarte, Mónica</creatorcontrib><creatorcontrib>García‐Morín, Marina</creatorcontrib><creatorcontrib>Ramos-Elbal, Eduardo</creatorcontrib><creatorcontrib>Ramírez, Manuel</creatorcontrib><creatorcontrib>Leukemia Working Group of the Spanish Society of Pediatric Hematology, Oncology (SEHOP)</creatorcontrib><creatorcontrib>the Leukemia Working Group of the Spanish Society of Pediatric Hematology, Oncology (SEHOP)</creatorcontrib><title>Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47·6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non‐haematological toxicity. The 12‐month overall survival and event‐free survival rates were 50·8 ± 26·4% and 38·9 ± 25·3% with blinatumomab, 45·8 ± 26% and 27·5 ± 25% with inotuzumab.</description><subject>acute lymphoblastic leukaemia</subject><subject>Acute lymphoblastic leukemia</subject><subject>Adolescent</subject><subject>Antibodies, Bispecific - administration & dosage</subject><subject>Antibodies, Bispecific - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>blinatumomab</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Infant</subject><subject>inotuzumab</subject><subject>Inotuzumab Ozogamicin - administration & dosage</subject><subject>Inotuzumab Ozogamicin - adverse effects</subject><subject>Leukemia</subject><subject>Male</subject><subject>Medical Oncology</subject><subject>Minimal residual disease</subject><subject>Monoclonal antibodies</subject><subject>Oncology</subject><subject>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality</subject><subject>relapse</subject><subject>Remission</subject><subject>Retrospective Studies</subject><subject>Societies, Medical</subject><subject>Spain - epidemiology</subject><subject>Stem cell transplantation</subject><subject>Survival Rate</subject><subject>Toxicity</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1DAUhiMEokNhwQsgS2zoIq1vuQw7piod0EhTaSqxjHw56XiaxMEXUHhP3gfPpLDDG-scf_9_jvxn2VuCL0k6V_KwvyRlyatn2YKwssgp4eR5tsAYVznBvD7LXnl_wJgwXJCX2RmjjHDG60X2e9WZQYTY215IJAaNzGBD_BWPZWsdWiEFXYdGByo6nxpCxQCom_pxb2UnfDAKdRAfBfRGJDVSe9NpB8NHJJCD4KwfQQXzA5APUU-odbZHYQ9ok1Qn0TfrHs3wgG6djSOy7el1N4rB-D3aWWUgTMf2HWgjgksD19CLYDv7MJ123g5qLj7sbtbbu4vX2YtWdB7ePN3n2f3nm_vrdb7Z3n65_rTJFavrKi-WbUVLplooZUtbAFnXWtCq0mwpKdF8qWSNOa8oF7ItWIVFIRghmha4lJqdZ-9n29HZ7xF8aA42uiFNbCjnhHJc0zpRFzOl0ld4B20zOtMLNzUEN8f8mpRfc8ovse-eHKPsQf8j_waWgKsZ-Gk6mP7v1Ky-rmfLPwhhqIw</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Fuster, José L.</creator><creator>Molinos‐Quintana, Agueda</creator><creator>Fuentes, Carolina</creator><creator>Fernández, José M.</creator><creator>Velasco, Pablo</creator><creator>Pascual, Toñi</creator><creator>Rives, Susana</creator><creator>Dapena, José L.</creator><creator>Sisinni, Luisa</creator><creator>López‐Godino, Oriana</creator><creator>Palomo, Pilar</creator><creator>Villa‐Alcázar, Marta</creator><creator>Bautista, Francisco</creator><creator>González‐Vicent, Marta</creator><creator>López‐Duarte, Mónica</creator><creator>García‐Morín, Marina</creator><creator>Ramos-Elbal, Eduardo</creator><creator>Ramírez, Manuel</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><orcidid>https://orcid.org/0000-0002-4881-9440</orcidid></search><sort><creationdate>202009</creationdate><title>Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)</title><author>Fuster, José L. ; Molinos‐Quintana, Agueda ; Fuentes, Carolina ; Fernández, José M. ; Velasco, Pablo ; Pascual, Toñi ; Rives, Susana ; Dapena, José L. ; Sisinni, Luisa ; López‐Godino, Oriana ; Palomo, Pilar ; Villa‐Alcázar, Marta ; Bautista, Francisco ; González‐Vicent, Marta ; López‐Duarte, Mónica ; García‐Morín, Marina ; Ramos-Elbal, Eduardo ; Ramírez, Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3887-59f7263cfe6bf2feeb88da277d39b21d49cb8044724abf5370a5a311d2506bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>acute lymphoblastic leukaemia</topic><topic>Acute lymphoblastic leukemia</topic><topic>Adolescent</topic><topic>Antibodies, Bispecific - administration & dosage</topic><topic>Antibodies, Bispecific - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>blinatumomab</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Infant</topic><topic>inotuzumab</topic><topic>Inotuzumab Ozogamicin - administration & dosage</topic><topic>Inotuzumab Ozogamicin - adverse effects</topic><topic>Leukemia</topic><topic>Male</topic><topic>Medical Oncology</topic><topic>Minimal residual disease</topic><topic>Monoclonal antibodies</topic><topic>Oncology</topic><topic>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality</topic><topic>relapse</topic><topic>Remission</topic><topic>Retrospective Studies</topic><topic>Societies, Medical</topic><topic>Spain - epidemiology</topic><topic>Stem cell transplantation</topic><topic>Survival Rate</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fuster, José L.</creatorcontrib><creatorcontrib>Molinos‐Quintana, Agueda</creatorcontrib><creatorcontrib>Fuentes, Carolina</creatorcontrib><creatorcontrib>Fernández, José M.</creatorcontrib><creatorcontrib>Velasco, Pablo</creatorcontrib><creatorcontrib>Pascual, Toñi</creatorcontrib><creatorcontrib>Rives, Susana</creatorcontrib><creatorcontrib>Dapena, José L.</creatorcontrib><creatorcontrib>Sisinni, Luisa</creatorcontrib><creatorcontrib>López‐Godino, Oriana</creatorcontrib><creatorcontrib>Palomo, Pilar</creatorcontrib><creatorcontrib>Villa‐Alcázar, Marta</creatorcontrib><creatorcontrib>Bautista, Francisco</creatorcontrib><creatorcontrib>González‐Vicent, Marta</creatorcontrib><creatorcontrib>López‐Duarte, Mónica</creatorcontrib><creatorcontrib>García‐Morín, Marina</creatorcontrib><creatorcontrib>Ramos-Elbal, Eduardo</creatorcontrib><creatorcontrib>Ramírez, Manuel</creatorcontrib><creatorcontrib>Leukemia Working Group of the Spanish Society of Pediatric Hematology, Oncology (SEHOP)</creatorcontrib><creatorcontrib>the Leukemia Working Group of the Spanish Society of Pediatric Hematology, Oncology (SEHOP)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fuster, José L.</au><au>Molinos‐Quintana, Agueda</au><au>Fuentes, Carolina</au><au>Fernández, José M.</au><au>Velasco, Pablo</au><au>Pascual, Toñi</au><au>Rives, Susana</au><au>Dapena, José L.</au><au>Sisinni, Luisa</au><au>López‐Godino, Oriana</au><au>Palomo, Pilar</au><au>Villa‐Alcázar, Marta</au><au>Bautista, Francisco</au><au>González‐Vicent, Marta</au><au>López‐Duarte, Mónica</au><au>García‐Morín, Marina</au><au>Ramos-Elbal, Eduardo</au><au>Ramírez, Manuel</au><aucorp>Leukemia Working Group of the Spanish Society of Pediatric Hematology, Oncology (SEHOP)</aucorp><aucorp>the Leukemia Working Group of the Spanish Society of Pediatric Hematology, Oncology (SEHOP)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2020-09</date><risdate>2020</risdate><volume>190</volume><issue>5</issue><spage>764</spage><epage>771</epage><pages>764-771</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47·6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non‐haematological toxicity. The 12‐month overall survival and event‐free survival rates were 50·8 ± 26·4% and 38·9 ± 25·3% with blinatumomab, 45·8 ± 26% and 27·5 ± 25% with inotuzumab.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>32314348</pmid><doi>10.1111/bjh.16647</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-4881-9440</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2020-09, Vol.190 (5), p.764-771 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_journals_2441240828 |
| source | MEDLINE; Access via Wiley Online Library; Wiley Online Library (Open Access Collection) |
| subjects | acute lymphoblastic leukaemia Acute lymphoblastic leukemia Adolescent Antibodies, Bispecific - administration & dosage Antibodies, Bispecific - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects blinatumomab Chemotherapy Child Child, Preschool Children Disease-Free Survival Female Hematology Humans Immunotherapy Infant inotuzumab Inotuzumab Ozogamicin - administration & dosage Inotuzumab Ozogamicin - adverse effects Leukemia Male Medical Oncology Minimal residual disease Monoclonal antibodies Oncology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality relapse Remission Retrospective Studies Societies, Medical Spain - epidemiology Stem cell transplantation Survival Rate Toxicity |
| title | Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A12%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blinatumomab%20and%20inotuzumab%20for%20B%20cell%20precursor%20acute%20lymphoblastic%20leukaemia%20in%20children:%20a%20retrospective%20study%20from%20the%20Leukemia%20Working%20Group%20of%20the%20Spanish%20Society%20of%20Pediatric%20Hematology%20and%20Oncology%20(SEHOP)&rft.jtitle=British%20journal%20of%20haematology&rft.au=Fuster,%20Jos%C3%A9%20L.&rft.aucorp=Leukemia%20Working%20Group%20of%20the%20Spanish%20Society%20of%20Pediatric%20Hematology,%20Oncology%20(SEHOP)&rft.date=2020-09&rft.volume=190&rft.issue=5&rft.spage=764&rft.epage=771&rft.pages=764-771&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.16647&rft_dat=%3Cproquest_cross%3E2441240828%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2441240828&rft_id=info:pmid/32314348&rfr_iscdi=true |